Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 4Recruiting 2Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 14Thoracic 13Head & Neck 7Tumor-Agnostic 4Dermatologic 3Sarcoma 1Other solid neoplasm 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Genitourinary 1CNS 1Breast 1

Conditions

Neoplasms 1Histiocytoma, Malignant Fibrous 1Dermatofibrosarcoma 1

Interventions

Radiotherapy 144Doxorubicin 112Temozolomide 110Cyclophosphamide 110Filgrastim 79Ifosfamide 70Imatinib Mesylate 69Etoposide 69Bevacizumab 55Vincristine 51Gemcitabine 50Peripheral Blood Stem Cell Transplantation 47Irinotecan 43Methotrexate 39Cisplatin 36Carboplatin 36Radiation 35fludarabine phosphate 34Busulfan 34pazopanib 32Sirolimus 30Melphalan 30Trabectedin 29Docetaxel 27Chemotherapy, Adjuvant 27Cyclosporine 25Carmustine 25sargramostim 24Surgical Procedures, Operative 23Sunitinib 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Immune Checkpoint Inhibitors × Sarcoma × Clear all
NCT03425279 2025-09-23

CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma

BioAtla, Inc.

Phase 1/2 Completed
245 enrolled
Sarcoma

Neoplasms, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡